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Background
The M184V mutation in HIV RT confers high-level
resistance to both 3TC and FTC and also has a strong
negative impact on viral replication capacity. In addition,
the presence of M184V is usually preceded by a M1841
mutation that results from a G®A hypermutation.
However, viruses that contain M184V usually outcom-
pete M184I due to higher replication ability; therefore
M184V becomes predominant. In contrast, the E138K
mutation in HIV-1 RT confers resistance to Rilpivirine
(RPV) and Etravirine(ETR), two NNRTIs, and also
impairs viral replication capacity. Phase III clinical trials
(ECHO & THRIVE ) showed that E138K/M184I are the
most frequent mutations in patients who received RPV
together with co-formulated TDF/ FTC,suggesting that
E138K might be a signature mutation for both ETR and
RPV. We have assessed the impact of E138K on enzy-
matic processivity, viral replication capacity, and drug
susceptibility in the context of M184I/V.
Methods
We studied recombinant HIV-1 RT enzymes and viruses
containing either the E138K and M184I/V mutations
alone and E1 38K-M1 84I/V in combination in regard
to enzyme processivity, polymerization rates, replication
capacity, and drug susceptibility.
Results
Tissue culture selections with ETR yielded E138K that
conferred modest (3-5-fold) resistance to this drug as
well as to efavirenz(EFV) and neviripine (NVP). These
susceptibilities were not altered in either viruses or RT
enzymes containing E138K together with M184I or
M184V. The relative replication capacity of HIV-1 con-
taining either E138K or M184I/V alone was decreased
by ~2- fold compared to wild-type (wt). In contrast, the
simultaneous presence of E138K and M184I/V was
shown to reverse this low fitness, and this result was
confirmed in cell-free experiments in which purified RT
enzymes containing E138K alone or E138K-M184I/V
double mutations displayed higher processivity than
eitherwt or M184I/V RT, especially at low dNTP con-
centrations. No significant differences were observed
between M184I and M184V in regard to these charac-
teristics. In addition, RT containing E138K or E138K
together with M184I/M184V possessed lower RNase H
activity than either wt RT or M184I/V RT.
Conclusions
The M184I/V mutations are the most prevalent among
treated individuals, but are only rarely found in trans-
mitted resistance due to their adverse impact on viral
replicative f tness. E138K has the potential to be an
important signature mutation for both ETR and RPV.
E138K can alsorestore the enzymatic processivity and
viral replication capacity of HIV-1 variants harbor-
ingM184I/V. If E138K is able to function as a compen-
satory mutation for M184I/V, this may have clinical and
public health importance in regard to treatment failures
involving ETR, RPV, and other novel NNRTIs as well as
on the detectability of these mutations in transmitted
resistance. These are the first reports of compensatory
mutations for the M184I/V mutations in HIV-1 RT.
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